Zobrazeno 1 - 10
of 18
pro vyhledávání: ''
Autor:
Atsuko Ogino, T. Kosaka, Marzia Capelletti, Jihyun Choi, Hideki Endoh, Junko Tanizaki, Michael J. Eck, Dalia Ercan, Magda Bahcall, Raymond M. Paranal, Geoffrey R. Oxnard, Pasi A. Jänne, Amanda J. Redig, Antonio Calles, Claire E. Repellin, Christine A. Lydon
Publikováno v:
Cancer Research. 77:2712-2721
Insertion mutations in EGFR and HER2 both occur at analogous positions in exon 20. Non–small cell lung cancer (NSCLC) patients with tumors harboring these mutations seldom achieve clinical responses to dacomitinib and afatinib, two covalent quinazo
Publikováno v:
Molecular Cancer Research. 13:659-669
KRAS mutations are frequently detected in human colorectal cancer and contribute to de novo apoptosis resistance and ultimately therapeutic failure. To overcome KRAS-mediated apoptosis resistance, the irreversible proteasome inhibitor, carfilzomib, w
Publikováno v:
Molecular Cancer Therapeutics. 8:2015-2026
Anticancer therapy with cisplatin and oxaliplatin is limited by toxicity and onset of tumor resistance. Both drugs form platinum-DNA cross-linked adducts, and cisplatin causes oxidative DNA damage including the 7,8-dihydro-8-oxo-2′-deoxyguanosine (
Publikováno v:
Molecular Cancer Therapeutics. 5:502-508
Irinotecan hydrochloride, a camptothecin derivative, is one of the most effective drugs for colorectal cancer, and SN-38 is its main active metabolite. Development of resistance is a major obstacle to the clinical application of this drug. We establi
Autor:
Elizabeth A. Maher, Balazs Halmos, Matthew Meyerson, Jeffrey C. Lee, Neal I. Lindeman, Victoria A. Joshi, Robert J. Distel, Pasi A. Jänne, Andrew M. Rogers, Ana M. Borras, Bruce E. Johnson, Hema Liyanage, Yanan Kuang
Publikováno v:
Clinical Cancer Research. 12:751-758
Purpose: Mutations in the epidermal growth factor receptor (EGFR) are associated with clinical and radiographic responses to EGFR tyrosine kinase inhibitors gefitinib and erlotinib. Currently available methods of EGFR mutation detection rely on direc
Autor:
Anthony E. Pegg, Aparecida Maria Fontes, Marco Antonio Zago, Brian Davis, Lawrence A. Loeb, Dimas Tadeu Covas, Stanton L. Gerson, Lance P. Encell, Karen Lingas
Publikováno v:
Molecular Cancer Therapeutics. 5:121-128
P140K-MGMT and G156A-MGMT genes encode two O6-benzylguanine–resistant O6-alkylguanine DNA alkyltransferase proteins that confer a high degree of O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) or O6-benzylguanine and temozolomide r
Autor:
Jennifer M. Kwan, Jody C. Chuang, Gangning Liang, Christine B. Yoo, Tony W.H. Li, Peter A. Jones, Allen S. Yang
Publikováno v:
Molecular Cancer Therapeutics. 4:1515-1520
DNA cytosine methylation plays a considerable role in normal development, gene regulation, and carcinogenesis. Hypermethylation of the promoters of some tumor suppressor genes and the associated silencing of these genes often occur in certain cancer
Publikováno v:
Cancer Research. 77:848-848
Melanoma is the most aggressive and deadliest type of skin cancer due to its high propensity to metastasize. Despite current progress in the identification of promising drugs for treating melanoma, drug resistance has emerged as a serious issue indic
Autor:
Barbara Rivera, Jian Carrot-Zhang, Ester Castellsagué, Jose G. Teodoro, David Barford, William D. Foulkes, Mohamed Moustafa, Isabelle Gamache, Jacek Majewski
Publikováno v:
Molecular Cancer Research. 14:PR13-PR13
Introduction: Cdc20 is a co-activator recruited by the anaphase-promoting complex (APC), a large, multi-subunit complex that functions as an Ubiqutin ligase that targets key substrates for degradation to promote cell cycle progression. During mitosis
Autor:
Hanumantha Rao Madala
Publikováno v:
Cancer Research. 76:3722-3722
There is an urgent need for the design and discovery of new and potent inhibitors for the DNA repair protein MGMT (O6-Methylguanine-DNA-methyltransferase) in glioma therapy. MGMT is highly expressed in brain tumors, and plays a primary role in confer